Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements, including statements relating to VPC's agreement to purchase an additional $750,000 senior secured note; the intended use of the proceeds of such note for working capital purposes; an asset impairment charge, related impact upon the Fortical manufacturing revenues and royalties, and further additional discussions relating thereto; the Company's path forward in continuing to explore and develop strategic options to protect and enhance shareholder value; the Company's ability to build a robust portfolio of proprietary partnerships in the peptide-based therapeutics area based on its Peptelligence platform; the Company's leadership in the design, delivery, manufacture and development of peptide-based therapeutics; and VPC's initiation of a public disposition of certain of the Company's assets, including the Company's Peptelligence drug delivery platform, pursuant to Article 9 of the Uniform Commercial Code . These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors. These known and unknown risk factors include, but are not limited to: the delay in obtaining or the failure to obtain regulatory approvals for our products and th
|SOURCE Unigene Laboratories, Inc.|
Copyright©2012 PR Newswire.
All rights reserved